DVAX Valuation

Dynavax Technologies Corp

Add to Watchlist

Advanced Chart

10.855

-0.125(-1.138%)1D

Overview
Forecast
Valuation
Earnings

DVAX Relative Valuation

DVAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DVAX is overvalued; if below, it's undervalued.

Historical Valuation

Dynavax Technologies Corp (DVAX) is now in the Fair zone, suggesting that its current forward PS ratio of 3.90 is considered Fairly compared with the five-year average of -6.02. The fair price of Dynavax Technologies Corp (DVAX) is between 9.16 to 19.05 according to relative valuation methord.

Relative Value

Fair Zone

9.16-19.05

Current Price：10.85

Fair

23.85

Trailing

Forward

44.93

EV/EBITDA

Dynavax Technologies Corp. (DVAX) has a current EV/EBITDA of 44.93. The 5-year average EV/EBITDA is 60.62. The thresholds are as follows: Strongly Undervalued below -335.24, Undervalued between -335.24 and -137.31, Fairly Valued between 258.54 and -137.31, Overvalued between 258.54 and 456.47, and Strongly Overvalued above 456.47. The current Forward EV/EBITDA of 44.93 falls within the Historic Trend Line -Fairly Valued range.

51.76

EV/EBIT

Dynavax Technologies Corp. (DVAX) has a current EV/EBIT of 51.76. The 5-year average EV/EBIT is 34.96. The thresholds are as follows: Strongly Undervalued below -124.45, Undervalued between -124.45 and -44.74, Fairly Valued between 114.67 and -44.74, Overvalued between 114.67 and 194.37, and Strongly Overvalued above 194.37. The current Forward EV/EBIT of 51.76 falls within the Historic Trend Line -Fairly Valued range.

3.90

Dynavax Technologies Corp. (DVAX) has a current PS of 3.90. The 5-year average PS is 4.53. The thresholds are as follows: Strongly Undervalued below 0.08, Undervalued between 0.08 and 2.31, Fairly Valued between 6.76 and 2.31, Overvalued between 6.76 and 8.98, and Strongly Overvalued above 8.98. The current Forward PS of 3.90 falls within the Historic Trend Line -Fairly Valued range.

14.66

P/OCF

Dynavax Technologies Corp. (DVAX) has a current P/OCF of 14.66. The 5-year average P/OCF is 32.23. The thresholds are as follows: Strongly Undervalued below -106.71, Undervalued between -106.71 and -37.24, Fairly Valued between 101.70 and -37.24, Overvalued between 101.70 and 171.17, and Strongly Overvalued above 171.17. The current Forward P/OCF of 14.66 falls within the Historic Trend Line -Fairly Valued range.

24.43

P/FCF

Dynavax Technologies Corp. (DVAX) has a current P/FCF of 24.43. The 5-year average P/FCF is 48.48. The thresholds are as follows: Strongly Undervalued below -333.15, Undervalued between -333.15 and -142.34, Fairly Valued between 239.29 and -142.34, Overvalued between 239.29 and 430.10, and Strongly Overvalued above 430.10. The current Forward P/FCF of 24.43 falls within the Historic Trend Line -Fairly Valued range.

Dynavax Technologies Corp (DVAX) has a current Price-to-Book (P/B) ratio of 2.60. Compared to its 3-year average P/B ratio of 2.68 , the current P/B ratio is approximately -3.02% higher. Relative to its 5-year average P/B ratio of 6.69, the current P/B ratio is about -61.10% higher. Dynavax Technologies Corp (DVAX) has a Forward Free Cash Flow (FCF) yield of approximately 4.02%. Compared to its 3-year average FCF yield of 5.47%, the current FCF yield is approximately -26.56% lower. Relative to its 5-year average FCF yield of 3.93% , the current FCF yield is about 2.35% lower.

2.60

P/B

Median3y

2.68

Median5y

6.69

4.02

FCF Yield

Median3y

5.47

Median5y

3.93

Competitors Valuation Multiple

The average P/S ratio for DVAX's competitors is 6.32, providing a benchmark for relative valuation. Dynavax Technologies Corp Corp (DVAX) exhibits a P/S ratio of 3.90, which is -38.18% above the industry average. Given its robust revenue growth of 34.21%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

DVAX.O

Dynavax Technologies Corp

Vera Therapeutics Inc

Loss

1.33B

NTLA.O

Intellia Therapeutics Inc

Dyne Therapeutics Inc

Loss

1.40B

WVE.O

WAVE Life Sciences Ltd

ANI Pharmaceuticals Inc

1.62

43.43%

1.37B

Performance Decomposition

Market capitalization of DVAX decreased by 2.14% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -17.17 to -140.98.

The secondary factor is the Revenue Growth, contributed 34.21%to the performance.

Overall, the performance of DVAX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

34.21%

50.79M → 68.16M

Revenue Growth

721.08%

-17.17 → -140.98

Margin Expansion

-757.43%

3.62 → -23.82

P/E Change

-2.14%